Provided by Tiger Trade Technology Pte. Ltd.

QYUNS-B

17.000
-0.290-1.68%
Volume:26.20K
Turnover:445.44K
Market Cap:3.79B
PE:12.06
High:17.120
Open:16.950
Low:16.800
Close:17.290
52wk High:33.920
52wk Low:13.210
Shares:223.00M
HK Float Shares:223.00M
Volume Ratio:0.33
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.410
ROE:101.58%
ROA:23.84%
PB:3.76
PE(LYR):12.06
PS:3.16

Loading ...

QYUNS-B repurchases 25,200 H shares for HKD 0.39 million, treasury stock rises to 3.07 million

Bulletin Express
·
Jun 04

QYUNS-B trims outstanding shares by 0.09% in May through HK$3.35 million repurchases, maintains public float compliance

Bulletin Express
·
Jun 04

QYUNS-B buys back 0.11 million H-shares; treasury stock rises to 3.05 million units

Bulletin Express
·
Jun 03

QYUNS-B Executes Share Buyback, Spending HKD 1.69 Million

Stock News
·
Jun 03

Qyuns Therapeutics buys back 57,200 H-shares; treasury stock climbs to 2.94 million

Bulletin Express
·
Jun 02

QYUNS-B (02509) Repurchases 174,400 Shares for Approximately HK$2.81 Million on June 1

Stock News
·
Jun 01

Qyuns Therapeutics Buys Back 174,400 H-Shares, Expands Treasury Stock to 2.88 Million Shares

Bulletin Express
·
Jun 01

Qyuns Therapeutics Updates Articles of Association: Clarifies Share Structure, Governance Framework and Dividend Policy

Bulletin Express
·
May 29

Qyuns Therapeutics dissolves supervisory committee as supervisors resign

Reuters
·
May 29

Qyuns Therapeutics repurchases 70,000 H-shares; treasury stock rises to 2.71 million units

Bulletin Express
·
May 28

BRIEF-Qyuns Therapeutics Co Receives Milestone Payment From Roche

Reuters
·
May 27

QYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N

Stock News
·
May 27

Qyuns Therapeutics receives Roche milestone payment after first QX031N Phase I patient dosed

Reuters
·
May 27

Qyuns Therapeutics Co - Receives Milestone Payment From Roche for First Participant Dosed in Phase I QX031n Trial

THOMSON REUTERS
·
May 27

QYUNS-B (02509) Allocates HK$2.19 Million for Share Buyback on May 27

Stock News
·
May 27

Qyuns Therapeutics files HKEX next-day return disclosing share repurchase at HKD 16.31 each

Reuters
·
May 27

Qyuns Therapeutics secures NMPA approval for biosimilar QX001S (Ustekinumab) in Crohn’s disease, in partnership with Zhongmei Huadong

Bulletin Express
·
May 21

QYUNS-B (02509) Gains Approval for Marketing Authorization and Supplemental Application of QX001S (Ustekinumab Injection) for Crohn's Disease

Stock News
·
May 21

Qyuns Therapeutics - Zhongmei Huadong Receives Approvals for QX001s (Ustekinumab Injection) for Crohn's Disease

THOMSON REUTERS
·
May 21

QYUNS-B (02509) Rises Over 3% Following Windward Bio's Completion of $165 Million Crossover Financing to Advance WIN027 Clinical Study

Stock News
·
May 11